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1. Introduction
  In USA, human prostate cancer is the most common 
carcinoma in males, and the second leading cause of cancer 
related mortality in men[1-3]. Recent years, the frequency of 
prostate cancer is increasing in China[4]. Prostate specific 
antigen (PSA) that is secreted by human prostate epithelial 
cells is a specific protein. Altering of PSA level in serum 
indicates initiation, development and metastasis of prostate 
cancer and predicts prognosis for tumor patients[5-7]. 
Recently, PSA functions as a main sensitive biomarker for 
clinical diagnosis, treatment and prognosis. PSA is mainly 
expressed in prostate cells and tissues and keeps a low 
concentration in serum under normal condition. During 
prostate cancer initiation, PSA is released into the blood 
due to cancer cell proliferation and rupture, which leads to 
a significant increase of PSA level in serum. Thus, elevated 
serum PAS level is a critical marker for clinical diagnosis 
of prostate cancer[8-11]. Human prostate epithelial cells 
specifically express PSA. Accordingly, detecting the level 
change of PSA in human prostate epithelial cells is more 
convenience and accurate for predicting development, 
metastasis and prognosis of prostate cancer.
  Luciferase, as a classic report molecule, is widely used 
to label cells and tissues. Living imaging technology is 
used to directly monitor cells and tissues change in living 
animals based on bioluminescence imaging[12,13]. Therefore, 
luciferase report gene was applied to prostate cancer in 
our study. Promoter sequence of PSA was inserted into 
luciferase reports gene plasmid to construct a pPSA-FL-
Luc plasmid. We established a tumor bearing SCID mouse 
model using LNCap cells with pPSA-FL-Luc transfection. 
Tumor growth and metastasis were tracked using 
bioluminescence imaging in mice. Our date indicate that 
PSA luciferase report plasmids are useful for monitoring 
growth and metastasis of prostate cancer in mice.
Objective: To construct a PSA luciferase report plasmid and monitor the growth and metastasis 
of prostate cancer after emasculation in SCID mice. Methods: PSA promoter sequence and 
luciferase gene were amplified by PCR and subsequently inserted into pZsGreen1-1 vector to 
construct pPSA-FL-Luc vector. LNCaP cells that were stably transfected with pPSA-FL-Luc 
were used to establish a SCID mouse xenograft model. Then, the growth and metastasis of prostate 
cancer were monitored via living imaging. Results: We successfully constructed a PSA luciferase 
plasmid, pPSA-FL-Luc. DHT enhanced luciferase activity in a concentration-dependent manner 
in 293T cells with pPSA-FL-Luc transfection. Prostate cancer SCID mouse model was established 
with pPSA-FL-Luc transfected LNCaP cells. In tumor bearing mice with or without emasculation, 
pPSA-FL-Luc plasmid was applied to monitored tumor growth and metastasis based on 
bioluminescence imaging. Conclusions: We construct a pPSA-FL-Luc plasmid, which stably 
expresses luciferase and can be applied to monitor tumor development in a prostate SCID mouse 
model.
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2. Materials and methods
2.1. Cell lines 
  The human prostate cancer cell line, LNCaP, and 
human embryonic kidney cell line, 293T (the Institute 
of Biochemistry and Cell Biology, Chinese Academy of 
Sciences, Shanghai, China), were cultured in complete 
RPMI-1640 (Gibco, Grand Island, NY, USA) containing 10% 
fetal bovine serum (FBS, Gibco) with 100 units/mL penicillin 
and 100 毺g/mL streptomycin (Sigma, St-Louis, MO, USA) in 
a humidified containing of 5% CO2 incubator at 37 曟.
2.2. Expression constructs 
  PGL3-Basic vector and pRL-TK vector were obtained 
from Promega Co. (Madison, WI, USA). pZsGreen 1-1 vector 
and pMD 18-T vector were purchased from Clontech Co. 
(Mountain View, CA, USA) and Takara Co. (Takara Bio, Shiga, 
Japan). PSA promoter cassette was amplified from genomic 
DNA, which was isolated from LNCaP cells, using forward 
primer CAC ATT GTT TGC TGC ACG TTG and reverse 
primer AGC TTG GGG CTG GGG AGC C. The length of PCR 
product was 655 bps. The PCR product connected to a pMD 
18-T vector to form pMD 18-PSA. The linear skeleton of 
pZsGreen1-1 and PSA promoter fragment were collected 
after pZsGreen1-1 and pMD 18-PSA vectors cutting with 
Sac栺 and Hind栿. T4 DNA ligase connected PSA promoter 
fragment to linear skeleton to construct a eukaryotic 
expression vector, which carried the PSA promoter and was 
named as pPSA-ZsGreen. The full length of firefly luciferase 
(FL-Luc) gene was cloned from pGL3-Basic vector, each 
incorporating BamH栺 and Not栺 restriction site. The FL-
Luc fragment and pPSA-ZsGreen vector were cut by BamH
栺 and Not栺. T4 DNA ligase connected FL-Luc fragment 
to pPSA-ZsGreen linear skeleton to construct a luciferase 
eukaryotic expression plasmid, which was started by PSA 
and named as pPSA-FL-Luc.
2.3. Detection of PSA luciferase report plsmid
  The human embryonic kidney cells, 293T, were seeded 
in 12 well plates after counting. When the cell confluence 
reached to 50%, pPSA-FL-Luc and pRL-TK plasmids 
were transfected into 293T cells using lipofectamine 2000 
(Invitrogen, Carlsbad, CA, USA). After 24 hours transfection, 
293T cells were treated with 0.1 nmol/L, 1.0 nmol/L, 10.0 nmol/L
and 50.0 nmol/L 100.0 nmol/L dihydrotestosterone (DHT), 
respectively, for 48 hours. Total proteins were isolated from 
293T cells and the expression of fluorescence was detected 
using a Dual Luciferase Reporter Gene Assay Kit (Promega, 
USA).
2.4. Cell tranfection and selection 
  LNCaP cells were seeded in 24 well plates and treated 
with different G418 (Sigma, USA) concentration (400 毺g/mL,
600 毺g/mL, 800 毺g/mL, 1 000 毺g/mL and 1 200 毺g/mL). 
The lowest concentration that killed all LNCaP cells after 
10 to 14 days treatment was selected for further studies. 
LNCaP cells were transfected with pPSA-FL-Luc using 
lipofectamine 2000. After 24 hours transfection, cells were 
cultured in medium with G418 and the medium was changed 
every 3 days. Cell colonies were selected and seeded in 96 
well plates for luciferase activity detection after 2 weeks 
treatment. The positive cells were further cultured in 
medium with G418 to obtain LNCap/Luc/PSA cell line, which 
was stably expressed luciferase report gene.
2.5. In vivo experiments
  SCID mice (SHANGHAI SLAC LABORATORY ANIMAL 
CO. LTD, Shanghai, China) were used to establish a SCID 
mouse xenograft model. 2伊106 LNCaP/Luc/PSA cells were 
inoculated subcutaneously into the flank of the SCID 
mouse. At week 8 after implantation, tumor nodes were 
explanted and divided into small pieces (1 mm伊1 mm伊1 
mm). Then, the xenograft tumor tissues were injected into 
the capsule of prostate in SCID mice under anesthesia. After 
6 weeks, mice were injected with 150 毺L D-luciferin (15 
mg/mL, Biotium, Hayward, CA, USA) via intraperitoneal 
injection followed by isoflurane for anesthetization. In vivo 
xenogen imaging was performed to observe the location 
and intensity of fluorescence in SCID mice. SCID mice 
were divided into two groups according to with or without 
testicular castration. 1, 3 and 5 weeks after resection, tumor 
growth and metastasis were compared between two groups 
based on bioluminescence imaging. All animal protocols 
were approved by the Institutional Animal Care and Use 
Committee of Zhejiang University.
2.6. Statistical analysis 
  Results are expressed as Mean依SD. Significance was 
established, with SPSS statistical package for Windows 
Version 19.0 (SPSS, Chicago, IL, USA), using ANOVA when 
appropriate. Difference were considered significant when
P <0.05. 
3. Results
3.1. Amplification of PSA promoter cassette 
  PSA promoter cassette was amplified from genomic DNA, 
which was isolated from LNCaP cells, using proper primers. 
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As shown in Figure 1, the length of PCR product was 
between 500 bps and 750 bps, which were consistent with 
the length of PSA promoter sequence (655 bps).
 
PSA            Marker
750 bp
500 bp
Figure 1. PCR result of PSA promoter sequence. 
There is a fragment between 500 bps and 750 bps, which was consistent 
with PSA promoter sequence.
3.2. pPSA-FL-Luc plasmid construction 
  PCR products were subcloned into pMD 18-T vector. 
Sequencing was used to confirm the correctness of PSA 
promoter sequence. PSA promoter cassette was connected 
to pZsGreen 1-1vector to construct pPSA-ZsGreen (Figure 
2A). Furthermore, the full length of firefly luciferase (FL-
Luc) gene was cloned from pGL3-Basic vector. The FL-Luc 
cassette was further moved into pPSA-ZsGreen using BamH
栺 and Not栺, resulting in pPSA-FL-Luc (Figure 2B).
a          b         c        d
A                                                                             B
 
Figure 2. Construction of pPSA-FL-Luc plasmid. 
A) pPSA-FL-Luc was identified by electrophoresis gel. a) pPSA-FL-
Luc recombinant plasmid. b) Enzyme-digested product of pPSA-FL-
Luc. c) DL5000 Marker. d) PCR amplification product of FL-Luc.
3.3. Functional identification of pPSA-FL-Luc 
  293T cells were seeded in 12 well plates and transfected 
with pPSA-FL-Luc and pRL-TK plasmids, respectively, 
using lipofectamine 2000. Tranfected 293T cells were treated 
with different concentration of DHT (0.1 nmol/L, 1.0 nmol/L,
10.0 nmol/L, 50.0 nmol/L and 100.0 nmol/L). After 48 hours 
treatment, total proteins were isolated from 293T cells 
and the expression of fluorescence was detected using 
a commercial kit. We found that luciferase activity was 
enhanced by DHT in a concentration-dependent manner, 
the overall comparison and the difference between each 
two groups were significant (P<0.05, Figure 3). Our data 
indicated that the pPSA-FL-Luc plasmid had a normal 
function.
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Figure 3. Luciferase activities in cells treated by DHT at different 
concentration. 
Luciferase activity was enhanced by DHT in a concentration-
dependent manner.
3.4. LNCaP/Luc/PSA cell line screening 
  pPSA-FL-Luc plasmids were transfected into prostate cell 
line, LNCaP. After 2 weeks selection by G418, cell clones 
were selected and cultured in 96 well plates. D-luciferin 
was added into each well and selected cells were expressed 
hyperfluorescence (Figure 4).
 
Figure 4. LNCap cells were expressed fluorescence. 
LNCaP cells that were transfected with pPSA-FL-Luc plasmids were 
selected by G418 for 2 weeks. White arrow indicated LNCaP/Luc/PSA 
cells. 
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3.5. Hormone sensitivity-prostate cancer mouse model was 
treated with castration 
  A SCID mouse xenograft model was established with 
LNCaP/Luc/PSA cells. SCID mice were injected with 
D-luciferin via intraperitoneal injection. In vivo xenogen 
imaging showed that the tumor located in the prostate of 
mice according to fluorescence (Figure 5A). Furthermore, 
bioluminescence imaging indicated that testicular castration 
slowed down tumor growth and metastasis in SCID mice 
(Figure 5B).
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Figure 5. Bioluminescence imaging of SCID mice. 
A) Bioluminescence imaging indicated that tumors were located in 
prostate of SCID mice. B) According to the intensity of fluorescence, 
testicular castration inhibited tumor growth and metastasis in SCID 
mice.
4. Discussion
  Prostate cancer is one of the most common malignant 
cancers in males. The incidence of prostate cancer 
is increasing along with age. Tumor metastasis is the 
leading cause of poor prognosis for patients with prostate 
cancer[14,15]. One of the critical causes for prostate cancer 
initiation is androgen oversecretion[16-18]. As PSA gene 
expression is regulated by androgen[19,20], monitoring of 
prostate cancer growth and metastasis using a PSA luciferase 
report plasmid based on bioluminescence imaging may be a 
novel and useful method.
  PSA gene locates on the long arm of chromosome 19 and 
consists with 5 exons and 4 introns. Its promoter contains a 
TATA-box, a GC-box and an androgen response element 
(ARE). In this study, Genomic DNA that was isolated from 
LNCaP cells was used as templates for PSA promoter 
sequence amplification. After gel electrophoresis, the 
fragment was retrieved and subcloned into a pMD 18-T 
vector. Next, FL-Luc cDNA was amplified from pGL3-Basic 
vector. Finally, pZsGreen 1-1 vector was used as a skeleton, 
PSA promoter cassette following FL-Luc cDNA were inserted 
into vector to construct a pPSA-FL-Luc report plasmid. To 
verify the correctness of pPSA-FL-Luc plasmid, 293T cells 
were transfected with pPSA-FL-Luc plasmids and treated 
with different concentration of DHT to start luciferase gene 
expression. Our results found that DHT increased luciferase 
activity in a concentration-dependent manner and the 
pPSA-FL-Luc plasmid was approved by these results.
  After expression vector construction, LNCaP cells were 
transfected with pPSA-FL-Luc plasmids and selected by 
G418 for 2 weeks. Alive cells were chosen and cultured 
in 96 well plates. Under bioluminescent system, LNCaP 
cells were expressed hyperfluorescence after fluorescein 
substrate incubation, suggesting that we got an LNCaP/Luc/
PSA cell line. Next, LNCaP/Luc/PSA cells were implanted 
into the flank of SCID mice via subcutaneous injection. 
After tumor formation, tumor nodes were divided into 
small pieces and transplanted into prostate of SCID mice 
via subcapsular injection to form an in situ tumor model. 6 
weeks after model establishment, D-luciferin was injected 
into SCID mice via intraperitoneal injection. In vivo xenogen 
imaging showed that the tumor located in the prostate of 
mice according to fluorescence. Furthermore, SCID mice, 
which underwent testicular castration, exhibited a slower 
tumor growth and less metastasis as compared with control 
mice under bioluminescence imaging. As compared with 
traditional method for tumor detection, in vivo xenogen 
imaging is a potent method, which can directly, sensitively 
and constantly track tumour progression[21,22].
  In conclusion, we construct a PSA luciferase report plasmid 
and subsequently establish an LNCaP/Luc/PSA cell line. 
LNCaP/Luc/PSA cells are used to establish an in situ prostate 
cancer model in SCID mouse. In vivo xenogen imaging 
monitors tumor growth and metastasis of prostate cancer in 
SCID mice with or without testicular castration based on the 
location and intensity of fluorescence.
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